Why Heartbeam Shares Are Skyrocketing 75% Higher
Why Heartbeam Shares Are Skyrocketing 75% Higher
$HeartBeam (BEAT.US)$ shares are trading higher by 76% to $2.20 Thursday morning after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
$HeartBeam (BEAT.US)$周四上午，该公司股价上涨76%，至2.20美元，此前该公司宣布，美国专利商标局发布了用于检测急性冠脉综合征和心律失常的12导联心电贴片监测器的专利。
Heartbeam says this builds on the company's growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.
哈特伯姆表示，这是建立在该公司不断增长的知识产权组合的基础上的，该组合能够在医疗环境之外实现12导联心电诊断。
"This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today," said HeartBeam CEO and Founder Branislav Vajdic.
该专利为我们突破性的心电贴片技术提供了额外的知识产权保护，以简单贴片的形式提供12导联心电功能，在大小和形状上与目前市场上现有的单导联心电贴片监测器相似。布拉尼斯拉夫·瓦季奇.
"Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability."
我们的12导联心电贴片技术有可能带来与当前12导联心电护理标准一致的诊断准确率，并可能因其缺血检测能力而对心电贴片市场产生颠覆性影响。“
See Also: Why Is Rhythm Pharmaceuticals Stock Down Today?
另见：Rhythm PharmPharmticals股票今日为何下跌？
According to data from Benzinga Pro, Heartbeam has a 52-week high of $5.47 and a 52-week low of $1.12.
根据Benzinga Pro的数据，HeartBeam的52周高点为5.47美元，52周低点为1.12美元。